285 related articles for article (PubMed ID: 34540702)
1. Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins.
Zhang J; Gao X; Yu L
Front Oncol; 2021; 11():741746. PubMed ID: 34540702
[TBL] [Abstract][Full Text] [Related]
2. Role of HDACs in normal and malignant hematopoiesis.
Wang P; Wang Z; Liu J
Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
[TBL] [Abstract][Full Text] [Related]
3. Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival.
Tickenbrock L; Klein HU; Trento C; Hascher A; Göllner S; Bäumer N; Kuss R; Agrawal S; Bug G; Serve H; Thiede C; Ehninger G; Stadt UZ; McClelland M; Wang Y; Becker A; Koschmieder S; Berdel WE; Dugas M; Müller-Tidow C;
Leuk Res; 2011 May; 35(5):620-5. PubMed ID: 21176959
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
5. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
6. A minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.
Fu L; Shi J; Liu A; Zhou L; Jiang M; Fu H; Xu K; Li D; Deng A; Zhang Q; Pang Y; Guo Y; Hu K; Zhou J; Wang Y; Huang W; Jing Y; Dou L; Wang L; Xu K; Ke X; Nervi C; Li Y; Yu L
Int J Cancer; 2017 Feb; 140(3):653-661. PubMed ID: 27770540
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases as therapeutic targets in hematologic malignancies.
Melnick A; Licht JD
Curr Opin Hematol; 2002 Jul; 9(4):322-32. PubMed ID: 12042707
[TBL] [Abstract][Full Text] [Related]
9. Targeting aberrant transcriptional repression in acute myeloid leukemia.
Moe-Behrens GH; Pandolfi PP
Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic mechanisms in acute myeloid leukemia.
Peters AH; Schwaller J
Prog Drug Res; 2011; 67():197-219. PubMed ID: 21141731
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
Heibert SW; Lutterbach B; Durst K; Wang L; Linggi B; Wu S; Wood L; Amann J; King D; Hou Y
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S31-4. PubMed ID: 11587363
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
13. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
Puccetti E; Obradovic D; Beissert T; Bianchini A; Washburn B; Chiaradonna F; Boehrer S; Hoelzer D; Ottmann OG; Pelicci PG; Nervi C; Ruthardt M
Cancer Res; 2002 Dec; 62(23):7050-8. PubMed ID: 12460926
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract][Full Text] [Related]
15. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases function as novel potential therapeutic targets for cancer.
Zhang H; Shang YP; Chen HY; Li J
Hepatol Res; 2017 Feb; 47(2):149-159. PubMed ID: 27457249
[TBL] [Abstract][Full Text] [Related]
17. Oncoproteins, heterochromatin silencing and microRNAs: a new link for leukemogenesis.
Nervi C; Fazi F; Grignani F
Epigenetics; 2008; 3(1):1-4. PubMed ID: 18416028
[TBL] [Abstract][Full Text] [Related]
18. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
19. Runx1/AML1 in normal and abnormal hematopoiesis.
Yamagata T; Maki K; Mitani K
Int J Hematol; 2005 Jul; 82(1):1-8. PubMed ID: 16105753
[TBL] [Abstract][Full Text] [Related]
20. Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts.
Gozzini A; Santini V
Ann Hematol; 2005 Dec; 84 Suppl 1():54-60. PubMed ID: 16228241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]